AI in life sciences market seen reaching $10.43B by 2030

The global market for artificial intelligence in life sciences is projected to rise from $3.59 billion in 2025 to $10.43 billion by 2030, according to a new report from The Business Research Company. Growth is being driven by genomics, digital lab tools, AI-powered automation and wider use of remote patient monitoring.

Why it matters: - AI is moving from a supporting tool to a core layer in life sciences research, diagnostics and lab operations. - The market forecast points to sustained demand for faster research cycles, more precise analysis and more automated workflows. - The growth outlook also signals expanding commercial opportunity for software vendors, biotech firms and healthcare technology companies.

What happened: - The Business Research Company published its Artificial Intelligence In Life Sciences Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the AI in life sciences market will grow from $3.59 billion in 2025 to $4.44 billion in 2026. - The report projects the market will reach $10.43 billion by 2030. - The forecast implies a 23.6% CAGR from 2025 to 2026 and a 23.8% CAGR through 2030. - The report says North America held the largest share of the global market in 2025. - The report says Asia-Pacific will be the fastest-growing region in the coming years.

The details: - AI in life sciences includes technologies used to accelerate workflows, improve decision-making and extract insights from complex biological data. - The report ties near-term growth to rising complexity in biological data, expanding genomics research, broader use of digital laboratory technologies, early AI adoption in biotechnology and demand for faster research cycles. - The report says future growth will also come from investment in personalized medicine, wider use of AI-powered lab automation, cloud-based life science platforms, stronger collaboration between technology and life science companies, and greater regulatory acceptance of AI-derived insights. - Remote patient monitoring is one cited driver of demand. - In April 2025, the Peterson Center on Healthcare reported that spending on remote therapeutic monitoring under Traditional Medicare rose from $2.2 million in 2022 to $10.4 million in 2023. - The Peterson Center on Healthcare also reported that 451,000 Medicare patients used RPM services in 2023. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The report is available with a free sample and the full report.

Between the lines: - The forecast suggests AI adoption in life sciences is broadening beyond experimental use into operational infrastructure. - The emphasis on personalized medicine, cloud platforms and lab automation points to a market shifting toward integrated, data-heavy systems rather than standalone tools. - The regional outlook indicates that established healthcare markets still dominate current spending, while faster adoption may emerge in Asia-Pacific.

What's next: - The market is expected to keep expanding as life sciences companies adopt more AI-enabled research, monitoring and lab systems. - Wider regulatory acceptance of AI-derived insights could remove one of the main barriers to commercialization. - The report's 2030 forecast suggests continued momentum for vendors serving drug discovery, diagnostics, genomics and lab automation.